Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Ryota Kikuchi, Vincent C. Peterkin, William J. Chiou, Sonia M. de Morais & Daniel A. J. Bow. (2017) Validation of a total IC50 method which enables in vitro assessment of transporter inhibition under semi-physiological conditions. Xenobiotica 47:9, pages 825-832.
Read now
Read now
Articles from other publishers (30)
Ziyang Shan, Xuemei Yang, Huihui Liu, Yafei Yuan, Yuan Xiao, Jing Nan, Wei Zhang, Wenqi Song, Jufang Wang, Feiwen Wei & Yanqing Zhang. (2023) Cryo-EM structures of human organic anion transporting polypeptide OATP1B1. Cell Research 33:12, pages 940-951.
Crossref
Crossref
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Hironao Okubo, Masanori Atsukawa, Tomomi Okubo, Hitoshi Ando, Eisuke Nakadera, Kenichi Ikejima & Akihito Nagahara. (2022) Gadoxetic acid-enhanced magnetic resonance imaging predicts hyperbilirubinemia induced by glecaprevir during hepatitis C virus treatment. Scientific Reports 12:1.
Crossref
Crossref
Libor Vítek. 2022. Carbon Monoxide in Drug Discovery. Carbon Monoxide in Drug Discovery
175
194
.
Noora Sjöstedt, Jeffry Adiwidjaja, William A. Murphy & Kim L.R. Brouwer. 2022. Drug Transporters. Drug Transporters
257
282
.
Yang Li, Zahra Talebi, Xihui Chen, Alex Sparreboom & Shuiying Hu. (2021) Endogenous Biomarkers for SLC Transporter-Mediated Drug-Drug Interaction Evaluation. Molecules 26:18, pages 5500.
Crossref
Crossref
Minjun Chen, Kristin Ashby & Yue Wu. 2021. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity. Transporters and Drug‐Metabolizing Enzymes in Drug Toxicity
11
39
.
Lindsey H.M. te Brake, Veronique de Jager, Kim Narunsky, Naadira Vanker, Elin M. Svensson, Patrick P.J. Phillips, Stephen H. Gillespie, Norbert Heinrich, Michael Hoelscher, Rodney Dawson, Andreas H. Diacon, Rob E. Aarnoutse & Martin J. Boeree. (2021)
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg
−1
rifampicin
. European Respiratory Journal 58:1, pages 2000955.
Crossref
Crossref
Péter Tátrai & Péter Krajcsi. (2020) Prediction of Drug-Induced Hyperbilirubinemia by In Vitro Testing. Pharmaceutics 12:8, pages 755.
Crossref
Crossref
Lukas Kovar, Christina Schräpel, Dominik Selzer, Yvonne Kohl, Robert Bals, Matthias Schwab & Thorsten Lehr. (2020) Physiologically-Based Pharmacokinetic (PBPK) Modeling of Buprenorphine in Adults, Children and Preterm Neonates. Pharmaceutics 12:6, pages 578.
Crossref
Crossref
Ruipu Sun, Ying Ying, Zhimin Tang, Ting Liu, Fuli Shi, Huixia Li, Taichen Guo, Shibo Huang & Ren Lai. (2019) The Emerging Role of the SLCO1B3 Protein in Cancer Resistance. Protein & Peptide Letters 27:1, pages 17-29.
Crossref
Crossref
Libor Vitek, Cristina Bellarosa & Claudio Tiribelli. (2019) Induction of Mild Hyperbilirubinemia: Hype or Real Therapeutic Opportunity?. Clinical Pharmacology & Therapeutics 106:3, pages 568-575.
Crossref
Crossref
Noppaket Singkham, Anchalee Avihingsanon, Narukjaporn Thammajaruk, Kiat Ruxrungtham, Torsak Bunupuradah, Sasisopin Kiertiburanakul, Ploenchan Chetchotisakd, David M Burger, Sean Emery & Baralee Punyawudho. (2019)
Influence of
CYP3A5
and
SLCO1B1
polymorphisms on atazanavir/r concentrations in Thai HIV-infected patients
. Pharmacogenomics 20:7, pages 517-527.
Crossref
Crossref
Rachel J. Church & Paul B. Watkins. (2018) Serum biomarkers of drug‐induced liver injury: Current status and future directions. Journal of Digestive Diseases 20:1, pages 2-10.
Crossref
Crossref
Hisham Qosa, Brittany R. Avaritt, Neil R. Hartman & Donna A. Volpe. (2018) In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia. Cancer Chemotherapy and Pharmacology 82:5, pages 795-802.
Crossref
Crossref
Nan Zhang, Jihong Shon, Myong-Jin Kim, Chongwoo Yu, Lei Zhang, Shiew-Mei Huang, LaiMing Lee, Doanh Tran & Li Li. (2018) Role of CYP3A in Oral Contraceptives Clearance. Clinical and Translational Science 11:3, pages 251-260.
Crossref
Crossref
Xiaoyan Chu, Grace Hoyee Chan & Raymond Evers. (2017) Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions. Journal of Pharmaceutical Sciences 106:9, pages 2357-2367.
Crossref
Crossref
Mohamad Shebley, Jinrong Liu, Olga Kavetskaia, Jens Sydor, Sonia M. de Morais, Volker Fischer, Marjoleen J.M.A. Nijsen & Daniel A.J. Bow. (2017) Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir. Drug Metabolism and Disposition 45:7, pages 755-764.
Crossref
Crossref
Ayman F. El‐Kattan. 2017. Oral Bioavailability Assessment. Oral Bioavailability Assessment
77
138
.
K Yang, C Battista, JL Woodhead, SH Stahl, JT Mettetal, PB Watkins, SQ Siler & BA Howell. (2017) Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters. Clinical Pharmacology & Therapeutics 101:4, pages 501-509.
Crossref
Crossref
Hironao Okubo, Tsuneo Kitamura, Hitoshi Ando, Hiroo Fukada, Yuki Igusa, Shigehiro Kokubu, Akihisa Miyazaki, Akio Fujimura, Shuichiro Shiina & Sumio Watanabe. (2017) Gadoxetic Acid-Enhanced MR Imaging Predicts Simeprevir-Induced Hyperbilirubinemia During Hepatitis C Virus Treatment: A Pilot Study. The Journal of Clinical Pharmacology 57:3, pages 369-375.
Crossref
Crossref
Kimberly Lapham, Jonathan Novak, Lisa D. Marroquin, Rachel Swiss, Shuzhen Qin, Christopher J. Strock, Renato Scialis, Michael D. Aleo, Thomas Schroeter, Heather Eng, A. David Rodrigues & Amit S. Kalgutkar. (2016) Inhibition of Hepatobiliary Transport Activity by the Antibacterial Agent Fusidic Acid: Insights into Factors Contributing to Conjugated Hyperbilirubinemia/Cholestasis. Chemical Research in Toxicology 29:10, pages 1778-1788.
Crossref
Crossref
Tarjinder Sahota, Meindert Danhof & Oscar Della Pasqua. (2016) Pharmacology-based toxicity assessment: towards quantitative risk prediction in humans. Mutagenesis 31:3, pages 359-374.
Crossref
Crossref
H. Eng, R. J. Scialis, C. J. Rotter, J. Lin, S. Lazzaro, M. V. Varma, L. Di, B. Feng, M. West & A. S. Kalgutkar. (2016) The Antimicrobial Agent Fusidic Acid Inhibits Organic Anion Transporting Polypeptide-Mediated Hepatic Clearance and May Potentiate Statin-Induced Myopathy. Drug Metabolism and Disposition 44:5, pages 692-699.
Crossref
Crossref
Xiuli Li, Kan Zhong, Zitao Guo, Dafang Zhong & Xiaoyan Chen. (2015) Fasiglifam (TAK-875) Inhibits Hepatobiliary Transporters: A Possible Factor Contributing to Fasiglifam-Induced Liver Injury. Drug Metabolism and Disposition 43:11, pages 1751-1759.
Crossref
Crossref
Xiaoyan Chu, Shian-Jiun Shih, Rachel Shaw, Hannes Hentze, Grace H. Chan, Karen Owens, Shubing Wang, Xiaoxin Cai, Deborah Newton, Jose Castro-Perez, Gino Salituro, Jairam Palamanda, Aaron Fernandis, Choon Keow Ng, Andy Liaw, Mary J. Savage & Raymond Evers. (2015) Evaluation of Cynomolgus Monkeys for the Identification of Endogenous Biomarkers for Hepatic Transporter Inhibition and as a Translatable Model to Predict Pharmacokinetic Interactions with Statins in Humans. Drug Metabolism and Disposition 43:6, pages 851-863.
Crossref
Crossref
Tomoko Watanabe, Manami Miyake, Toshinobu Shimizu, Miho Kamezawa, Naoya Masutomi, Takesada Shimura & Rikiya Ohashi. (2015) Utility of Bilirubins and Bile Acids as Endogenous Biomarkers for the Inhibition of Hepatic Transporters. Drug Metabolism and Disposition 43:4, pages 459-466.
Crossref
Crossref
Rucha S. Sane, Gerhard G. Steinmann, Qihong Huang, Yongmei Li, Lalitha Podila, Kirsten Mease, Stephen Olson, Mitchell E. Taub, Jerry O. Stern, Gerhard Nehmiz, Wulf O. Böcher, Tarik Asselah & Donald Tweedie. (2014) Mechanisms Underlying Benign and Reversible Unconjugated Hyperbilirubinemia Observed with Faldaprevir Administration in Hepatitis C Virus Patients. Journal of Pharmacology and Experimental Therapeutics 351:2, pages 403-412.
Crossref
Crossref
Giulia BortolussiLorena ZentillinJana VaníkovaLuka BockorCristina BellarosaAntonio MancarellaEleonora VianelloClaudio TiribelliMauro GiaccaLibor VitekAndrés F. Muro. (2014) Life-Long Correction of Hyperbilirubinemia with a Neonatal Liver-Specific AAV-Mediated Gene Transfer in a Lethal Mouse Model of Crigler–Najjar Syndrome. Human Gene Therapy 25:9, pages 844-855.
Crossref
Crossref
Tomomi Furihata, Shogo Matsumoto, Zhongguo Fu, Akihito Tsubota, Yuchen Sun, Sayaka Matsumoto, Kaoru Kobayashi & Kan Chiba. (2014) Different Interaction Profiles of Direct-Acting Anti-Hepatitis C Virus Agents with Human Organic Anion Transporting Polypeptides. Antimicrobial Agents and Chemotherapy 58:8, pages 4555-4564.
Crossref
Crossref